New cancer drug JMT108 enters human testing
NCT ID NCT06877650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an experimental drug called JMT108, given alone or with other cancer drugs (pembrolizumab or ivonescimab), in people with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. About 436 adults are being enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JMT108 (an experimental drug given by IV every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1/2 trial, so the main goal is safety and dosing, not yet proof of effectiveness. Many experimental cancer drugs fail to show benefit in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets cancer growth at the genetic level
- New drug duo shows promise for tough cancers
- New cancer drug LBL-033 tested in 26 patients – safety first
- New cancer drug SG2918 enters first human tests
- Two-Antibody combo takes on advanced cancers
- New drug cocktail shows promise against tough cancers